These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36120112)

  • 1. Post-exposure prophylaxis to prevent varicella in immunocompromised children.
    Yamaguchi M; Tetsuka N; Okumura T; Haruta K; Suzuki T; Torii Y; Kawada JI; Ito Y
    Infect Prev Pract; 2022 Dec; 4(4):100242. PubMed ID: 36120112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
    Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
    Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir.
    Shinjoh M; Takahashi T
    J Hosp Infect; 2009 Jun; 72(2):163-8. PubMed ID: 19282055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
    Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
    Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing varicella zoster infection in immunocompromised adults with varicella zoster-specific immunoglobulins.
    Gelman D; Zektser M; Nesher L
    Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e94. PubMed ID: 37256153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
    Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
    Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella-zoster virus infection in immunocompromised patients.
    Masaoka T; Hiraoka A; Teshima H; Tominaga N
    J Med Virol; 1993; Suppl 1():82-4. PubMed ID: 8245898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early relapses of varicella-zoster virus infection in immunocompromised children treated with acyclovir.
    Mészner Z; Gyarmati E; Nyerges G; Simon M; Koller M
    Acta Paediatr Hung; 1990; 30(2):263-70. PubMed ID: 2248805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Incidence of Varicella Zoster Virus Disease in Adults Receiving Single-Unit Cord Blood Transplantation.
    Fukushi K; Konuma T; Monna-Oiwa M; Isobe M; Kato S; Kuroda S; Takahashi S; Nannya Y
    Transplant Cell Ther; 2022 Jun; 28(6):339.e1-339.e7. PubMed ID: 35364334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing varicella in children with malignancies: what is the evidence?
    Fisher JP; Bate J; Hambleton S
    Curr Opin Infect Dis; 2011 Jun; 24(3):203-11. PubMed ID: 21455062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varicella Zoster Virus-Associated Meningitis as a Rebound Varicella Zoster Disease after Antiviral Discontinuation.
    Sato T; Yamamoto T; Aoyama Y
    Case Rep Dermatol; 2021; 13(1):148-153. PubMed ID: 33790759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance testing of clinical varicella-zoster virus strains.
    Sauerbrei A; Taut J; Zell R; Wutzler P
    Antiviral Res; 2011 Jun; 90(3):242-7. PubMed ID: 21539861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEPtalk 3: oral aciclovir is equivalent to varicella zoster immunoglobulin as postexposure prophylaxis against chickenpox in children with cancer - results of a multicentre UK evaluation.
    Cuerden C; Gower C; Brown K; Heath PT; Andrews N; Amirthalingam G; Bate J
    Arch Dis Child; 2022 Jul; ():. PubMed ID: 35803693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary varicella-zoster virus infection--current knowledge, diagnostic and therapeutic approaches].
    Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I
    Med Pregl; 2000; 53(5-6):272-6. PubMed ID: 11089369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral acyclovir prophylaxis of varicella after intimate contact.
    Lin TY; Huang YC; Ning HC; Hsueh C
    Pediatr Infect Dis J; 1997 Dec; 16(12):1162-5. PubMed ID: 9427463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varicella-zoster virus.
    Arvin AM
    Clin Microbiol Rev; 1996 Jul; 9(3):361-81. PubMed ID: 8809466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of plasma exchange with a high dose of acyclovir for disseminated varicella infection.
    Aoyagi J; Kanai T; Maru T; Odaka J; Saito T; Betsui H; Yamagata T
    CEN Case Rep; 2020 Feb; 9(1):15-18. PubMed ID: 31520251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
    König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
    Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.
    Kim SK; Kim MC; Han SB; Kim SK; Lee JW; Chung NG; Cho B; Jeong DC; Kang JH; Kim HK
    Blood Res; 2016 Dec; 51(4):249-255. PubMed ID: 28090487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of varicella zoster virus infections.
    Snoeck R; Andrei G; De Clercq E
    Int J Antimicrob Agents; 1994 Aug; 4(3):211-26. PubMed ID: 18611613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.